Liposarcoma Market to Grow Significantly During the Forecast Period (2022-32) | Key Players – Janssen, Karyopharm, Novartis, GlaxoSmithKline, Incyte, Macrogenics, Adaptimmune, TerSera, Syndivia

Liposarcoma Market to Grow Significantly During the Forecast Period (2022-32) | Key Players - Janssen, Karyopharm, Novartis, GlaxoSmithKline, Incyte, Macrogenics, Adaptimmune, TerSera, Syndivia
Delveinsight Business Research LLP
As per DelveInsight, the Liposarcoma Therapeutics Market dynamics are expected to transform immensely in the upcoming years owing to the extensive research and development (R&D) activities of pharmaceutical companies and the expected launch of approved therapies in the market.

DelveInsight’s “Liposarcoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Liposarcoma market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Liposarcoma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Liposarcoma Market

Liposarcoma: An Overview

According to the National Organization of Rare Disorders (NORD), “Liposarcoma (LPS) is a rare tumor derived from fat tissue that occurs in the “soft tissues” of the body (soft tissue sarcoma). It is classified as cancer (malignant) because of its potential to recur locally and spread to other areas of the body.”

The severity of the disease depends on the subtype of the liposarcoma and the presenting stage of the primary tumor. It can arise in various locations throughout the body, although it is most frequently found in the extremities, particularly in the thigh. It can also grow in the back of the abdomen in an area called the “retroperitoneum” where, because of the vast amount of space, it can effectively hide a tumor of substantial size and weight. Some individuals with liposarcoma may not have symptoms in the early stages, but as the tumor grows and advances to later stages, it can potentially compress other tissues and cause pain.

The most critical step in diagnosing liposarcoma involves taking a biopsy of the mass of concern. Liposarcoma can also be diagnosed by imaging the body either by computed tomography (CT) or magnetic resonance imaging (MRI).

Liposarcoma Market Key Facts

  • As per NORD, Liposarcoma is a soft tissue sarcoma affecting approximately 2000 individuals each year in the United States. The incidence is approximately 1 per 100, 000 persons/years.

  • Liposarcoma affects men more than women, and more specifically, middle-aged men ranging from 50–65 years of age. Children are rarely diagnosed, but when liposarcoma does occur in children, it is usually during adolescence. There is no specific ethnicity in which liposarcoma is more common.

  • Internationally, with an annual incidence of 2.5 cases per million population, liposarcoma is the most common soft tissue sarcoma, accounting for approximately 17% of all soft tissue sarcomas and 3% of all liposarcomas in the head and neck region (usually the neck and the cheek).

Liposarcoma Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Liposarcoma market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Liposarcoma market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Liposarcoma Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Liposarcoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Liposarcoma market or expected to get launched during the study period. The analysis covers the Liposarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Liposarcoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Liposarcoma Market Will Evolve by 2032 @

The Leading companies in the Liposarcoma market include:

Sanofi, Janssen, Eisai, Rain Therapeutics, Karyopharm Therapeutics, GlaxoSmithKline, Novartis, Incyte Corporation, Mirati Therapeutics, Karyopharm Therapeutics, Pfizer, Macrogenics, Adaptimmune, Merck KGaA, Immune Design, Syndivia, TerSera Therapeutics, and many others.

Liposarcoma therapies covered in the report include:

  • DS-3032

  • Selinexor

  • INCMGA00012

  • Sitravatinib

  • Cabazitaxel

  • RAIN-32

  • Selinexor

And many others. 

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Liposarcoma Competitive Intelligence Analysis

4. Liposarcoma Market Overview at a Glance

5. Liposarcoma Disease Background and Overview

6. Liposarcoma Patient Journey

7. Liposarcoma Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Liposarcoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Liposarcoma Unmet Needs

10. Key Endpoints of Liposarcoma Treatment

11. Liposarcoma Marketed Products

12. Liposarcoma Emerging Drugs and Latest Therapeutic Advances

13. Liposarcoma Seven Major Market Analysis

14. Attribute Analysis

15. Liposarcoma Market Outlook (In US, EU5, and Japan)

16. Liposarcoma Access and Reimbursement Overview

17. KOL Views on the Liposarcoma Market

18. Liposarcoma Market Drivers

19. Liposarcoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

Other Trending Healthcare Reports By DelveInsight

Liposarcoma Pipeline Insights

“Liposarcoma – Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ drugs in the Liposarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States